ClinConnect ClinConnect Logo
Search / Trial NCT06337383

Study of the Prevalence of Autistic Traits in Angelman Syndrome

Launched by IRCCS EUGENIO MEDEA · Mar 21, 2024

Trial Information

Current as of July 25, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how common autism spectrum disorder (ASD) is in children and teenagers who have Angelman syndrome, a genetic condition that affects development. The researchers want to understand the differences between kids with Angelman syndrome who have autism traits and those who do not. They will look at various factors, such as genetics, epilepsy, behavior problems, and how parents manage stress, to see how these might relate to autism traits.

To be eligible for this study, children must be between 4 and 15 years old and have a confirmed diagnosis of Angelman syndrome. Participants will undergo regular assessments that include tests for cognitive development and social skills. Parents will also provide information about their parenting styles and stress levels. The study is currently looking for participants, and it's a great opportunity to contribute to understanding how autism interacts with Angelman syndrome, potentially leading to better support for families.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • genetically confirmed diagnosis of Angelman Syndrome
  • chronological age between 4-15 years
  • Exclusion Criteria:
  • genetic examination pending report
  • mental age lower than 12 months
  • brain injury acquired in the peri- or postnatal period

About Irccs Eugenio Medea

IRCCS Eugenio Medea is a leading clinical research institute based in Italy, dedicated to advancing pediatric healthcare through innovative research and evidence-based practices. As a recognized center of excellence, it focuses on multidisciplinary approaches to address complex health challenges in children and adolescents, particularly in the fields of neurodevelopmental disorders, mental health, and rehabilitation. The institute collaborates with national and international partners to conduct rigorous clinical trials, aiming to translate scientific discoveries into effective therapeutic interventions. Committed to enhancing patient outcomes, IRCCS Eugenio Medea prioritizes ethical standards and patient safety in all its research endeavors.

Locations

Conegliano, Treviso, Italy

Patients applied

0 patients applied

Trial Officials

Martina Baggio

Principal Investigator

Scientific Institute IRCCS E. Medea, Epilepsy Unit, Conegliano 31015, Italy

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported